www.beautysageist.com • Professional Insights • Expert Commentary • Resource Center
www.beautysageist.com

Quality Check,authorized

Is Tirzepatide Approved for Weight Loss in Canada? Nov 1, 2023—Currently itis only approved for use in diabetes in both the US and Canada. Healthcare providers trained in obesity medicine and eager to help 

:Wegovy is formally approved for use in weight management in Canada

A
Billy Gonzalez

focuses '' on consumer behavior and preferences and shares research-based knowledge on YouTube and TikTok

Published on

Executive Summary

Tirzepatide Nov 1, 2023—Currently itis only approved for use in diabetes in both the US and Canada. Healthcare providers trained in obesity medicine and eager to help 

The question of whether tirzepatide is approved for weight loss in Canada has been a significant point of discussion for many Canadians seeking effective weight management solutions. While Mounjaro (the brand name for tirzepatide when used for type 2 diabetes) has been available in Canada for some time, its specific approval for chronic weight management is a more recent development.

Health Canada has officially approved Zepbound™ KwikPen® (tirzepatide injection) for chronic weight management. This dual-acting medication, which targets both GLP-1 and GIP receptors, represents a significant advancement in pharmacotherapies for obesity. Previously, Canadians seeking tirzepatide for weight loss often relied on off-label prescriptions for Mounjaro. However, with the approval of Zepbound, there is now a dedicated formulation for weight management in Canada.

Tirzepatide is authorized for once-weekly administration as an adjunct to a reduced-calorie diet and increased physical activity. It is indicated for chronic weight management, including weight loss and weight maintenance, in adult patients who are obese or overweight with at least one weight-related comorbidity. This means that while the medication is a powerful tool, it is intended to be used in conjunction with lifestyle modifications to achieve and sustain weight loss.

It's important to distinguish between the indications for Mounjaro and Zepbound. While Mounjaro has been approved in Canada since 2022 primarily for type 2 diabetes, Zepbound specifically received Health Canada-approved status for chronic weight management. This signifies a targeted approach to addressing obesity as a medical condition.

The journey to this approval involved rigorous clinical trials demonstrating the efficacy of tirzepatide in promoting significant weight loss. Studies have shown that tirzepatide is superior to other weight management medications like semaglutide (marketed as Wegovy and Ozempic) in head-to-head comparisons. For instance, Wegovy is formally approved for weight management in Canada, and while Zepbound has now received that formalized approval, it's crucial to note the specific indications for each.

For Canadian residents, the availability of Zepbound means that healthcare providers trained in obesity medicine can now prescribe this medication with confidence for its intended purpose. While some insurance providers may still be reviewing coverage for Zepbound, the Health Canada-approved indication marks a critical step forward. The Mounjaro helps in weight loss by reducing food intake and slowing down digestion, and Zepbound leverages these mechanisms for a weight-focused indication.

It is crucial to consult with a qualified healthcare professional to determine if tirzepatide is the right treatment option for you. They can assess your individual health status, discuss potential benefits and risks, and guide you on the appropriate dosage and treatment plan. Remember, tirzepatide is a prescription medication and should only be used under the supervision of a medical doctor. The cost of tirzepatide in Canada can vary, and discussing insurance coverage with your provider is recommended.

Related Articles

Frequently Asked Questions

Here are the most common questions about .

Jul 10, 2025—It is the first and onlyHealth Canada-approved dual receptor agonist for chronic weight management, including weight loss and weight 
Dec 18, 2025—Mounjaro (Tirzepatide) is a GLP-1 and GIP dual-agonist injectable medication that iscurrently approved for diabetes treatment in Canada. It 
Is Tirzepatide A Miracle Weight Loss Peptide Or Hype?
Health Canada has officially approved Zepbound (tirzepatide) for weight management! While Mounjaro has been around for type 2 diabetes in Canada for a while.

Leave a Comment

Share your thoughts, feedback, or additional insights on this topic.

Explore More